Murdoch Childrens Research Institute
mcri.edu.auTotal trials
90
Active
34
Phase 3
15
Total enrollment
199,930
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 27 of 27 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oral cefalexin only | — | — | — | — | — | 1 | |
| IV cefazolin or IV flucloxacillin followed by oral cefalexin | — | — | — | — | — | 1 | |
| Vitamin D | — | — | — | — | — | 1 | |
| Morphine | — | — | — | — | — | 1 | |
| Oxycodone | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Benzylpenicillin - single dose | — | — | — | — | — | 1 | |
| Benzylpenicillin - three days | — | — | — | — | — | 1 | |
| Gentamicin - single dose | — | — | — | — | — | 1 | |
| Gentamicin - three days | — | — | — | — | — | 1 | |
| Cefalexin - post single dose of IV antibiotics for the remaining two days | — | — | — | — | — | 1 | |
| Antibiotics for duration of symptoms | — | — | — | — | — | 1 | |
| Antibiotics for duration of prescribed course | — | — | — | — | — | 1 | |
| Remifentanil | — | — | — | — | 2 | ||
| Dexmedetomidine | — | — | — | — | 2 | ||
| Bivalent Moderna | — | — | — | — | — | 2 | |
| Sevoflurane | — | — | — | — | — | 1 | |
| Novavax | — | — | — | — | — | 1 | |
| Alpelisib | — | — | — | — | — | 1 | |
| Mirdametinib | — | — | — | — | — | 1 | |
| Ivermectin | — | — | — | — | — | 1 | |
| Medicinal Cannabis - C12T12 | — | — | — | — | — | 1 | |
| Medicinal Cannabis - C20T5 | — | — | — | — | — | 1 | |
| Standard dosing of IV ganciclovir | — | — | — | — | — | 1 | |
| Personalised dosing of IV ganciclovir | — | — | — | — | — | 1 | |
| Omeprazole | — | — | — | — | — | 1 | |
| Dextromethorphan | — | — | — | — | — | 1 |
Next readouts
- 2024-10-13
- 2026-03
- 2026-03-19
- 2026-06
- 2026-07
- 2026-10
- 2026-12
- 2027-01
- 2027-08
- 2028-04
Top conditions
- COVID-199
- Infection4
- Sepsis4
- Dermatitis, Atopic3
- Allergy3
- Cellulitis3
- Respiratory Tract Infections3
- Bacteremia3
Frequently asked questions about Murdoch Childrens Research Institute
- How many clinical trials does Murdoch Childrens Research Institute have on ClinicalTrials.gov?
- Murdoch Childrens Research Institute is listed as the lead sponsor on 90 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Murdoch Childrens Research Institute's trials are in Phase 3?
- 15 of Murdoch Childrens Research Institute's trials are in Phase 3, spread across 27 active drug programs.
- What therapeutic areas does Murdoch Childrens Research Institute focus on?
- Murdoch Childrens Research Institute's most-studied conditions on ClinicalTrials.gov are COVID-19, Infection, Sepsis, Dermatitis, Atopic, Allergy.
- When are Murdoch Childrens Research Institute's next clinical trial readouts?
- Murdoch Childrens Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “COVID-19 Booster Study in Healthy Adults in Australia”, expected around 2024-10-13.